Neuronal glucose metabolism and schizophrenia: Therapeutic prospects?

Expert Review of Neurotherapeutics

Volumn 3, Issue 1, 2003, Pages 29-40

  Dwyer, Donard S ^a   Lux, Xiao Hong ^a   Freeman III, Arthur M ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Aripiprazole; Clozapine; Glucose metabolism; Neuroenhancement; Olanzapine; Quetiapine; Risperidone; Schizophrenia; Ziprasidone

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BRAIN DEVELOPMENT; CELL SURVIVAL; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GRAY MATTER; HUMAN; NERVE CELL DIFFERENTIATION; NERVE FUNCTION; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; REVIEW; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 0037229150     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.1.29     Document Type: Review

References (120)

1. Rice DP. The economic impact of schizophrenia. J. Clin. Psychiatry 60 (Suppl. 1), 4-6 (1999).
2. Gillberg C, Wahlstrom J, Forsman A, Hellgren L, Gillberg IC. Teenage psychoses - epidemiology, classification and reduced optimality in the pre-, peri- and neonatal periods. J. Child Psychol. Psychiatry 27, 87-98 (1986).
3. Stephenson J. Children with mental problems not getting the care they need. JAMA 284, 2043-2044 (2000).
4. Kelleher KJ, Mdnemy TK, Gardner WP, Childs GE, Wasserman RC. Increasing identification of psychosocial problems: 1979-1996. Pediatrics 105, 1313-1321 (2000).
5. Jensen PS, Vitiello B, Leonard H, Laughren TP. Design and methodology issues for clinical treatment trials in children and adolescents. Psychopharmacol. Bull. 30, 3-8 (1994).
6. Findling RL, Schulz C, Reed MD, Blumer JL. The antipsychotics: a pediatric perspective. Child Adoles. Psychopharmacol. 45, 1205-1232 (1998). Excellent summary of clinical trials in children and adolescents.
7. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch E. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283, 1025-1030 (2000). Highlights the problems of prescribing psychotropic drugs to young children.
8. Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J. Risperidone in adolescents with schizophrenia: an open pilot study. J. Am. Acad. Child Adolesec. Psychiatry 36, 694-700 (1997).
9. Toren P, Laor N, Weizman A. Use of atypical neuroleptics in child and adolescent psychiatry. J. Clin. Psychiatry 59, 644-656 (1998). Excellent summary of clinical trials in children and adolescents.
10. Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability and differential sensitivity to extrapyramidal symptoms. Can. J. Psychiatry 43, 596-604 (1998). Excellent summary of clinical trials in children and adolescents.
11. Vitiello B. Pediatric psychopharmacology and the interaction between drugs and the developing brain. Can. J. Psychiatry 43, 582-584 (1998). Emphasizes the potential interactions between drugs and the developing CNS.
12. Coyle JT. Psychotropic drug use in very young children. JAMA 283, 1059-1060 (2000).
13. Wyatt RJ. Early intervention for schizophrenia: can the course of the illness be altered? Biol Pychiatry 38, 1-3 (1995).
14. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J. Psychiatry Res. 17, 319-334 (1982). Seminal paper on the neurodevelopmental theory of schizophrenia.
15. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44, 660-669 (1987). Seminal paper on the neurodevelopmental theory of schizophrenia.
16. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. BioL Psychiatry 45, 17-25 (2000).
17. McGlashan TH, Hoffman RE. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch. Gen. Psychiatry 57, 637-648 (2000).
18. Lewis DA, Levitt P. Schizophrenia as a disorder of neurodevelopment. Ann. Rev. Neurosci. 25, 409-432 (2002). Excellent review of theories of the etiology of schizophrenia.
19. Giedd JN, Jeffries NO, Blumenthal J et al. Childhood-onset schizophrenia: progressive brain changes during adolescence. Biol. Psychiatry 46, 892-898 (1999).
20. Thompson PM, Vidal C, Giedd JN et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc. Natl Acad Sci. USA 98, 11650-11655 (2001). Critical paper showing loss of gray matter in early-onset schizophrenia in children.
21. Sokoloff L. Circulation and energy metabolism of the brain. In: Basic Neurochemistry. Siegel GJ, Albers RW, Katzman R, Agranoff BW (Eds), Little Brown and Company, Boston, MA, USA, 388-413 (1976).
22. Blass JP. Glucose/mitochondria in neurological conditions. Int. Rev. Neurobiol. 51, 326-376 (2002).
23. Newcomer JW, Craft S, Fucetola R et al. Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr. Bull. 25, 321-335 (1999).
24. Dwyer DS, Bradley RJ, Kablinger AS, Freeman AM III. Glucose metabolism in relation to schizophrenia and antipsychotic drugs. Ann. Clin Psychiatry 13, 103-113 (2001). Reviews numerous connections between schizophrenia and glucose metabolism.
25. Moises HW, Zoega T, Gottesman II. The glial growth factor deficiency and synaptic destabilization hypothesis of schizophrenia. BMC Psychiatry 2, 8-21 (2002).
26. Hajduch E, Litherland GJ, Hundal HS. Protein kinase B (PKB/Akt) - a key regulator of glucose transport? FEBS Lett. 492, 199-203 (2001).
27. Baquer NZ, Hothersall JS, McLean P. Function and regulation of the pentose phosphate pathway in brain. Curr. Topics Cell Reg. 29, 265-289 (1988).
28. Tian W-N, Braunstein LD, Apse K, Pang J, Stanton RC. Importance of glucose-6-phosphate dehydrogenase activity in cell death. Am J. Physiol 276, C1121-C1131 (1999).
29. Seeman P. Atypical antipsychotics: mechanism of action. Can J. Psychiatry 47, 27-38 (2002).
30. Birmaher B, Baker R, Kapur S, Quintana H, Ganguli R. Clozapine for the treatment of adolescents with schizophrenia. J. Am. Acad. Child Adolesc. Psychiatry 31, 160-164 (1992).
31. Chalasani L, Kant R, Chengappa KN. Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia. Can. J. Pychiatry 46, 965-968 (2001).
32. Kumra S, Frazier JA, Jacobsen LK et al. Childhood-onset schizophrenia. A double-blind dozapine-haloperidol comparison. Arch. Gen. Psychiatry 53, 1090-1097 (1996).
33. Turetz M, Mozes T, Toren P et al. An open trial of dozapine in neuroleptic-resistant childhood-onset schizophrenia. Br. J. Psychiatry 170, 507-510 (1997).
34. Meltzer HY, McGurk SR. The effects of dozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25, 233-255 (1999). Very useful summary of clinical studies on the cognitive effects of antipsychotic drugs.
35. Purdon SE, Labelle A, Boulay L. Neuropsychological change in schizophrenia after 6weeks of dozapine. Schizophr. Res. 48, 57-67 (2001).
36. Potkin SG, Fleming K, Jin Y, Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J Clin. Psychopharmacol. 21, 479-483 (2001).
37. Bilder RM, Goldman RS, Volavka J. et al. Neurocognitive effects of dozapine, olanzapine, risperidone and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry 159, 1018-1028 (2002).
38. Goldberg TE, Weinberger DR. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. J. Clin. Psychiatry 57(Suppl. 9), 62-65 (1996).
39. Hoff AL, Faustman WO, Wieneke M et al. The effects of dozapine on symptom reduction, neurocognitive function and clinical management in treatment refractory state hospital schizophrenic in-patients. Neuropsychopharmacology 15, 361-369 (1996).
40. Dwyer DS, Pinkofsky HB, Liu Y, Bradley RJ. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 23, 69-80 (1999).
41. Dwyer DS, Liu Y, Bradley RJ. Dopamine receptor antagonists modulate glucose uptake in rat pheochromocytoma (PC12) cells. Neurosci. Lett. 274, 151-154 (1999).
42. Ardizzone TD, Bradley RJ, Freeman AM III, Dwyer DS. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and dozapine and structural analogs of dozapine. Brain Res. 923, 82-90 (2001).
43. Hagg S, Joelsson L, Mjomdal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin. Pychiatry 59, 294-299 (1998).
44. Henderson DC, Cagliero E, Gray C et al. Clozapine, diabetes mellicus, weight gain and lipid abnormalities: A five-year naturalistic study. Am. J. Psychiatry 157, 975-981 (2000). Essential paper for those interested in the link between antipsychotic drugs and diabetes.
45. Donohoe D, Dwyer DS. Induction of hyperglycemia in mice by administration of antipsychotic drugs. FASEBJ. 16, A568 (2002).
46. Dwyer DS, Ardizzone TD, Bradley RJ. Psychoactive drugs affect glucose transport and the regulation of glucose metabolism. Int. Rev. Neurobiol. 51, 503-530 (2002).
47. Dwyer DS, Lu X-H, Bradley RJ. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Under review (2002).
48. Quintana H, Keshavan M. Case study: Risperidone in children and adolescents with schizophrenia. J. Am. Acad Child Adolesc. Psychiatry 34, 1292-1296 (1995).
49. Greevich SJ, Findling RL, Rowane WA, Friedman L, Schulz SC. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J. Child Adolesc. Pychopharmacol. 6, 251-257 (1996).
50. Simeon J, Milin P, Walker S. A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 26, 267-275 (2002).
51. Cannon TD, Huttunen MO, Dahlstrom M, Larmo I, Rasanen P, Juriloo A. Antipsychotic drug treatment in the prodromal phase of schizophrenia. Am. J. Psychiatry 159, 1230-1232 (2002). Provides first solid attempt to treat prodromal schizophrenia.
52. Sharma T, Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. J. Clin. Psychopharmacol. 18(2 Suppl. 1), 12S-19S (1998).
53. Green MF, Marder SR, Glynn SM et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol. Psychiatry 51, 972-978 (2002). Critical analysis of the neurocognitive effects of the antipsychotic drugs.
54. Carpenter WT Jr, Gold JM. Another view of therapy for cognition in schizophrenia. Biol. Psychiatry 51, 969-971 (2002). Critical analysis of the neurocognitive effects of the antipsychotic drugs.
55. Frazier JA, Biederman J, Tohen M et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J. Child Adolesc. Psychopharmacol. 11, 239-250 (2001).
56. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J. Am. Acad. Child Adolesc. Psychiatry 40, 887-894 (2001).
57. Malek-Ahmadi P, Simonds JE. Olanzapine for autistic disorder with hyperactivity. J. Am. Acad. Child Adolesc. Psychiatry 37, 902 (1998).
58. Kemner C, Willemsen-Swinkels SH, De Jonge M, Tuynman-Qua H, Van Engeland H. Open-label study of olanzapine in children with pervasive developmental disorder. J. Clin. Psychopharmacol. 22, 455-460 (2002).
59. Kumra S, Jacobsen LK, Lenane M et al. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J. Am. Acad. Child Adolesc. Psychiatry 37, 377-385 (1998).
60. Mandoki M. Olanzapine in the treatment of early onset schizophrenia in children and adolescents. Biol. Psychiatry 41, 22S (1997).
61. Haapsalo-Pesu KM, Saarijarvi S. Olanzapine induces remarkable weight gain in adolescent patients. Eur. Child Adolesc. Psychiatry 10, 205-208 (2001).
62. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am. J. Psychiatry 156, 79-87 (1999).
63. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schiwpbr. Res. 48, 17-28 (2001).
64. Purdon SE, Jones BDW, Stip E et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol. Arch. Gen. Psychiatry 57, 249-258 (2000).
65. Smith RC, Infante M, Singh A, Khandat A. The effect of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. Int. J. Neuropsychopharmacol. 4, 239-250 (2001).
66. Grove VE Jr, Quintanilla J, DeVaney GT. Improvement in Huntington's disease with olanzapine and valproate. N. Engl. J. Med. 343, 973-974 (2000).
67. Agarwal V, Kumar P. Olanzapine in the treatment of tardive dyskinesia. J. Clin. Psychiatry 62, 298-299 (2001).
68. Lu X-H, Bradley RJ, Dwyer DS. Neuroenhancing effects of olanzapine are mediated via the P13K/Akt pathway and glucose transport regulation. Submitted for publication (2002).
69. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J. Cell Sci. 114, 2903-2910 (2001).
70. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am. J. Psychiatry 159, 655-657 (2002).
71. Szigethy E, Brent S, Findling RL. Quetiapine for refractory schizophrenia. J. Am. Acad Child Adolesc. Psychiatry 37, 1127-1128 (1998).
72. Healy E, Subotsky F, Pipe R. Quetiapine in adolescent psychosis. J. Am. Acad. Child Adolesc. Psychiatry 38, 1329 (1999).
73. McConville BJ, Arvanitis LA, Thyrum PT et al. Pharmacokinetics, tolerability and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J. Clin. Psychiatry 61, 252-260 (2000).
74. Shaw JA, Lewls JE, Pascal S et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J. Child Adolesc. Psychopharmacol. 11, 415-424 (2001).
75. Fleming K, Thyrum P, Yeh C, Vargu DL, Potkin SG. Cognitive improvements in psychotic subjects treated with 'Seroquel' (quetiapine fumarate): an exploratory study. J. Clin. Psychopharmacol. 21, 527-529 (2001).
76. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatry Neurosci. 26, 137-149 (2001).
77. Velligan DI, Newcomer J, Pultz J et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr. Res. 53, 239-248 (2002).
78. Sallee FR, Kudan R, Goetz CG et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J. Am. Acad. Child Adolesc. Psychiatry 39, 292-299 (2000).
79. Patel NC, Sierk P, Dorson PG, Crismon MI. Experience with ziprasidone. J. Am. Acad Child Adolesc. Pychiatry 41, 495 (2002).
80. Goodnick PJ. Ziprasidone: profile on safety. Expert Opinion Pharmacother. 2, 1655-1662 (2001).
81. Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302, 381-389 (2002). Discusses an interesting new antipsychotic drug.
82. 1A receptor. Eur. J. Pharmacol. 441, 137-140 (2002).
83. Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripriprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 63, 763-771 (2002).
84. Newcomer JW, Haupt DW, Fucetola R et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry 59, 337-345 (2002). Excellent review of abnormalities in glucose metabolism induced by antipsychotic drugs.
85. Ratzoni G, Gothelf D, Brand-Gothelf A et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J. Am. Acad. Child Adolesc. Psychiatry 41, 337-343 (2002).
86. Tsuang MT, Stone WS, Faraone SV. Towards the prevention of schizophrenia. Biol. Psychiatry 48, 349-356 (2000). Important overview of the field.
87. Kan O, Baldwin S, Whetton A. Apoptosis is regulated by the rate of glucose transport in an interleukin-3-dependent cell line. J. Exp. Med. 180, 917-923 (1994).
88. Berridge MV, Tan AS. Interleukin-3 facilitates glucose transport in a myeloid cell line by regulating the affinity of the glucose transporter for glucose: involvement of protein phosphorylation in transporter activation. Biochem. J. 305, 843-851 (1995).
89. Dwyer DS, Liu Y, Bradley RJ. An ethanol-sensitive variant of the PC12 neuronal cell line: sensitivity to ethanol is associated with increased cell adhesion and decreased glucose accumulation. J. Cell Physiol. 178, 93-101 (1999).
90. Moley KH, Mueckler MNL. Glucose transport and apoptosis. Apoptosis 5, 99-105 (2000).
91. Gupta A, Ho DY, Brooke S et al. Neuroprotective effects of an adenoviral vector expressing the glucose transporter: a detailed description of the mediating cellular events. Brain Res. 908, 49-57 (2001).
92. Gold PE. Role of glucose in regulating the brain and cognition. Am J. Clin. Nutr. 61(4 Suppl.), 987S-995S (1995).
93. Korol DL. Enhancing cognitive function across the lifespan. Ann. NY Acad. Sci. 959, 167-179 (2002).
94. Azari NP. Effects of glucose on memory processes in young adults. Psychopharmacology 105, 521-524 (1991).
95. Craft S, Asthana S, Schellenberg G et al. Insulin effects on glucose metabolism, memory and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann. NYAcad Sci. 903, 222-228 (2000).
96. Bondy CA, Cheng CM. Insulin-like growth factor-1 promotes neuronal glucose utilization during brain development and repair processes. Int. Rev. Neurobiol. 51, 189-217 (2002).
97. Bedwell JS, Keller B, Smith AK, Hamburger S, Kumra S, Rapoport JL. Why does postpsychotic IQ decline in childhood-onset schizophrenia? Am. J. Psychiatry 156, 1996-1997 (1999).
98. Cosway R, Byrne M, Clafferty R et al. Neuropsychological change in young people at high risk for schizophrenia: results from the first two neuropsychological assessments of the Edinburgh High Risk Study. Psychol. Med. 30, 1111-1121 (2000).
99. Rowley M, Bristow L, Hutson PH. Current and novel approaches to the drug treatment of schizophrenia. J. Med. Chem. 44, 477-501 (2001).
100. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol. Psychiatry 45, 1-16 (1999).
101. Dwyer DS, Vannucci SJ, Simpson IA. Expression, regulation and functional role of glucose transporters (GLUTs) in brain. Int. Rev. Neurobiol. 51, 159-188 (2002).
102. Gruetter R, Seaquist ER, Ugurbil K. A mathematical model of compartmentalized neurotransmitter metabolism in the human brain. Am. J. Physiol. 281, E100-E112 (2001).
103. Magistretti PJ, Pellerin L, Rothman DI, Shulman RG. Energy on demand. Science 283, 496-497 (1999).
104. Tamminga CA. Schizophrenia and glutamate transmission. Crit. Rev. Neurobiol. 12, 21-36 (1998).
105. Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 61, 75-111 (2000).
106. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am. J. Psychiatry 155, 1490-1501 (1998).
107. de Leon J, Becona E, Gurpegui M, Gonzalez-Pinto A, Diaz FJ. The association between high nicotine dependence and severe mental illness may be consistent across countries. J. Clin. Pychiatry 63, 812-816 (2002).
108. Duelli R, Staudt R, Gruenwald F, Kuschinsky W. Increase of glucose transporter densities (GLUT1 and GLUT3) during chronic administration of nicotine in rat brain. Brain Res. 782, 36-42 (1998).
109. Boado RJ. Brain-derived peptides regulate the steady-state levels and increase stability of the blood-brain barrier GLUT1 glucose transporter mRNA. Neurosci. Lett. 197, 179-182 (1995).
110. Cheng CM, Reinhardt RR, Lee W-H, Joncas G, Patel SC, Bondy CA. Insulin-like growth factor 1 regulates developing brain glucose metabolism. Proc. Natl Acad. Sci. USA 97, 10236-10241 (2000).
111. Panisset M, Gauthier S, Moessler H, Windisch M. The Cerebrolysin Study Group. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. J. Neural Transm. 109, 1089-1104 (2002).
112. Simpson IA, Chundu K, Davies-Hill T, Honer WG, Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann. Neurol. 35, 546-551 (1994).
113. Heininger K. A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events. Rev. Neurosci. 11, 213-328 (2000). Thought-provoking article.
114. Cooper JR, Pincus JH. The role of thiamine in nervous tissue. Neurochem Res. 4, 223-239 (1979).
115. Iwata H, Yabushita Y, Doi T, Matsuda T. Synthesis of thiamine triphosphate in rat brain in vivo. Neurochem. Res. 10, 779-787 (1985).
116. Feinberg JE. The Wemicke-Korsakoff syndrome. Am. Fam. Physician 22, 129-133 (1980).
117. Sacks W, Esser AH, Feitel B, Abbott K. Acetazolamide and thiamine: an ancillary therapy for chronic mental illness. Psychiatry Res. 28, 279-288 (1989).
118. Chalecka-Franaszek E, Chuang D-M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl Acad. Sci. USA 96, 8745-8750 (1999).
119. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J. Neurochem. 75, 1729-1734 (2000).
120. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Menji HK. Lithium-induced increase in human brain grey matter. Lancet 356, 1241-1242 (2000). Very interesting paper.